Developmental Diseases and Conditions -

Autism; Investigators from Marcus Autism

Center Report New Data on Autism (Using a
Patient-Centered Outcome Measure to Test
Methylphenidate Versus Placebo in Children
with Autism Spectrum Disorder)
Publication info: Pediatrics Week ; Atlanta [Atlanta]29 Apr 2017: 305.

ProQuest document link

ABSTRACT (ENGLISH)
According to news originating from Atlanta, Georgia, by VerticalNews correspondents, research stated, "Parent
rating scales are commonly used to evaluate change in clinical trials. According to the news editors, the research
concluded: "The parent target problem method offers a systematic way to identify and track patient-centered
outcomes." Atlanta, Georgia, United States, North and Central America, Norepinephrine-Dopamine Reuptake
Inhibitors, Developmental Diseases and Conditions, Developmental Disabilities, Psychotherapeutic Agents,
Methylphenidate, Phenylacetates, Mental Health, Pediatrics, Neurology, Autism, Marcus Autism...

FULL TEXT
2017 APR 29 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- Fresh data on Developmental
Diseases and Conditions - Autism are presented in a new report. According to news originating from Atlanta,
Georgia, by VerticalNews correspondents, research stated, "Parent rating scales are commonly used to evaluate
change in clinical trials. Despite advantages, these measures may not capture parental impression of the child's
most salient problems."
Our news journalists obtained a quote from the research from Marcus Autism Center, "We examine the use of
parent target problems (PTPs) in a randomized trial of methylphenidate (MPH) in children with autism
spectrumdisorder and symptoms of attentiondeficit/ hyperactivity disorder. This multisite, 4-week, randomized
crossover trial compared three dose levels (low, medium, and high) of MPH with placebo. At baseline, the
independent evaluator (IE) asked parents to nominate the child's two biggest problems. For each problem, the IE
and parent coconstructed a brief narrative of the behavior and the impact on family life. The IE and parents
reviewed and revised the narratives at subsequent visits. A panel of four judges, blind to treatment condition,
independently reviewed the narratives to rate change from baseline on a 9-point scale: 1, normal; 2, markedly
improved; 3, definitely improved; 4, equivocally improved; 5, no change; 6, possibly worse; 7, definitely worse; 8,
markedly worse; 9, disastrously worse. The mean of the four raters was compared with primary and key secondary
ratings from the original study. Two PTPs were recorded at baseline for 60 participants. The inter-rater reliability of
the four judges across all PTPs and time points was excellent (intraclass correlation = 0.95). On the primary
outcome measure (Aberrant Behavior Checklist Hyperactivity subscale), the medium and high-dose levels were
superior to placebo. On the mean PTP rating, only the high dose was superior to placebo. We also compared PTP
cutoff scores 3.0 (definitely improved), 3.25, and 3.5 with the rate of positive response on the Improvement item of
the Clinical Global Impressions scale in the original study. Sensitivities ranged from 68% to 88%."
According to the news editors, the research concluded: "The parent target problem method offers a systematic
way to identify and track patient-centered outcomes."

PDF GENERATED BY SEARCH.PROQUEST.COM Page 1 of 3

For more information on this research see: Using a Patient-Centered Outcome Measure to Test Methylphenidate
Versus Placebo in Children with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology,
2017;27(2):125-131. Journal of Child and Adolescent Psychopharmacology can be contacted at: Mary Ann Liebert,
Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - www.liebertpub.com;
Journal of Child and Adolescent Psychopharmacology - www.liebertpub.com/overview/journal-of-child-and-
adolescent-psychopharmacology/29/)
The news correspondents report that additional information may be obtained from L. Scahill, Marcus Autism
Center, Atlanta, GA 30329, United States. Additional authors for this research include K. Bearss, R. Sarhangian, C.J.
McDougle, L.E. Arnold, M.G. Aman, J.T. McCracken, E. Tierney, S. Gillespie, V. Postorino and B. Vitiello.
Keywords for this news article include: Atlanta, Georgia, United States, North and Central America, Norepinephrine-
Dopamine Reuptake Inhibitors, Developmental Diseases and Conditions, Developmental Disabilities,
Psychotherapeutic Agents, Methylphenidate, Phenylacetates, Mental Health, Pediatrics, Neurology, Autism,
Marcus Autism Center.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx
LLC

DETAILS

Subject: Autism; Psychopharmacology; Children &youth; Pediatrics; Narratives

Location: United States--US Atlanta Georgia Georgia

Identifier / keyword: City:Atlanta State:Georgia Country:United States Region:North and Central America
Norepinephrine-Dopamine Reuptake Inhibitors Developmental Diseases and
Conditions Developmental Disabilities Psychotherapeutic Agents Methylphenidate
Phenylacetates Mental Health Pediatrics Neurology Autism

Publication title: Pediatrics Week; Atlanta

First page: 305

Publication year: 2017

Publication date: Apr 29, 2017

Publisher: NewsRx

Place of publication: Atlanta

Country of publication: United States, Atlanta

Publication subject: Medical Sciences--Pediatrics

ISSN: 1944-2637

Source type: Wire Feeds

Language of publication: English

PDF GENERATED BY SEARCH.PROQUEST.COM Page 2 of 3

 Document type: Expanded Reporting

ProQuest document ID: 1889885313

Document URL: https://search.proquest.com/docview/1889885313?accountid=46437

Copyright: Copyright 2017, NewsRx LLC

Last updated: 2017-04-20

Database: Health &Medical Collection

Database copyright  2018 ProQuest LLC. All rights reserved.

Terms and Conditions Contact ProQuest

PDF GENERATED BY SEARCH.PROQUEST.COM Page 3 of 3